Know Cancer

forgot password

Phase II Trial of SOM230 (Pasireotide LAR) in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Phase 2
18 Years
Open (Enrolling)
Hepatocellular Carcinoma

Thank you

Trial Information

Phase II Trial of SOM230 (Pasireotide LAR) in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Inclusion Criteria:

- Diagnosis of unresectable HCC by either:

- Histopathology or

- Elevated serum AFP > 400 ng/ml and findings on magnetic resonance imaging (MRI)
or CT scans characteristic of a primary liver tumor.

- Age ≥ 18 years.

- Minimum of four weeks since any major surgery, completion of radiation,or completion
of all prior systemic anticancer therapy (adequately recovered from the acute
toxicities of any prior therapy).

- Patients may have progressed on sorafenib or refused or were intolerant of
sorafenib. A maximum of 2 prior lines of systemic therapy (including chemotherapy or
targeted therapy) will be allowed. Prior locoregional therapy such as surgery,
radiofrequency ablation or transarterial chemoembolization are also allowed (these
will not be counted as systemic therapy), provided that progression has been
documented after these therapies, and at least 4 weeks have elapsed since the last

- Karnofsky performance status (KPS) of 80 or Eastern Cooperative Oncology Group(ECOG)
performance status of 0 or 1.

- Life expectancy 12 weeks or more.

- Adequate bone marrow function as shown by: ANC ≥ 1.2 x 10^9/L, Platelets ≥ 100 x

- Adequate liver function as shown by: serum bilirubin < 1.5x ULN and serum
transaminases activity ≤ 3 x ULN. Serum PT =< 16 seconds.

- Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN.

- Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤
2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient
can only be included after initiation of appropriate lipid lowering medication.

- Women of childbearing potential must have a negative serum pregnancy test within 14
days of the administration of the first study treatment. Women must not be
lactating. Both men and women of childbearing potential must be advised of the
importance of using effective birth control measures during the course of the study.

- Signed informed consent to participate in the study must be obtained from patients
after they have been fully informed of the nature and potential risks by the
investigator (or his/her designee) with the aid of written information.

- Child's A and early Child's B (no more than 7 points on the Child Pugh

- Measurable disease or evaluable disease by CT scan with contrast. If evaluable
disease or measurable disease has been previously treated, this must show signs of
tumor progression by CT. Measurable disease and evaluable disease will be defined by
the RECIST guidelines (see section 9.0).

Exclusion Criteria:

- Prior octreotide therapy or any somatostatin analog.

- Chronic treatment with systemic steroids or another immunosuppressive agent.

- Patients should not receive immunization with attenuated live vaccines during study
period or within 1 week of study entry.

- Uncontrolled brain or leptomeningeal metastases, including patients who continue to
require glucocorticoids for brain or leptomeningeal metastases.

- Patients with prior or concurrent malignancy except for the following: adequately
treated basal cell or squamous cell skin cancer, or other adequately treated in situ
cancer, or any other cancer from which the patient has been disease free for five

- Patients with uncontrolled diabetes mellitus (defined as HgA1c > 7% or =8% despite
therapy) or a fasting plasma glucose > 1.5 ULN. Note: At the principle investigator's
discretion, non-eligible patients can be re-screened after adequate medical therapy
has been instituted.

- Patients with symptomatic cholelithiasis

- Patients who have congestive heart failure (NYHA Class III or IV), unstable
angina,sustained ventricular tachycardia, ventricular fibrillation, clinically
significant bradycardia, advanced heart block or a history of acute myocardial
infarction within the six months preceding enrollment.

- Patients who are at high risk for cardiac arrhythmias as defined by any of the

- Baseline QTcF > 450 msec

- History of syncope or family history of idiopathic sudden death or long QT

- Sustained or clinically significant cardiac arrhythmias

- Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia,
cardiac failure, clinically significant/symptomatic bradycardia, or high-grade
AV block

- Concomitant disease(s) that could prolong QT such as autonomic neuropathy
(caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled
hypothyroidism or cardiac failure

- Concomitant medication(s) known to increase the QT interval (see Appendix II)

- Patients with the presence of active or suspected acute or chronic uncontrolled
infection or with a history of immunocompromise, including a positive HIV test result
(ELISA and Western blot).

- Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation in the study such as:

- Severely impaired lung function

- Any active (acute or chronic) or uncontrolled infection/ disorders.

- Nonmalignant medical illnesses that are uncontrolled or whose control may be
jeopardized by the treatment with the study therapy

- Women who are pregnant or breast feeding, or women/men able to conceive and unwilling
to practice an effective method of birth control. (Women of childbearing potential
must have a negative serum pregnancy test within 14 days prior to administration of
pasireotide). Oral, implantable, or injectable contraceptives may be affected by
cytochrome P450 interactions, and are therefore not considered effective for this

- Known hypersensitivity to somatostatin analogues or any component of the pasireotide
or octreotide LAR formulations

- History of noncompliance to medical regimens

- Patients unwilling to or unable to comply with the protocol or unable to give
informed consent.

- Patients with baseline ALT or AST > 3x ULN.

- Patients with baseline serum bilirubin > 1.5 x ULN.

- PT > 16 seconds and/or PTT > 1.5 x ULN

- History of or current alcohol misuse/abuse within the past 12 months.

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy: Number of patients achieving response to SOM230 treatment of either CR, PR or SD

Outcome Description:

The primary objective of this trial is to assess the efficacy of SOM230 in patients with advanced, unresectable hepatocellular carcinoma. The primary endpoint is the disease-control rate defined as the proportion of patients achieving a best overall response of either a "Complete Response (CR)", Partial Response (PR), or Stable Disease (SD).

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

Lynn Feun, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Miami Sylvester Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

July 2012

Completion Date:

Related Keywords:

  • Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • HCC
  • SOMO230
  • Pasireotide LAR
  • Carcinoma
  • Carcinoma, Hepatocellular



University of Miami Sylvester Comprehensive Cancer CenterMiami, Florida  33136